Skip to main content

Vision Medicals Gets CE Mark for SARS-CoV-2 Clinical Sequencing Test

NEW YORK – Vision Medicals has received the CE-IVD mark for its SARS-CoV-2 Clinical Sequencing assay, which uses next-generation sequencing.

The test is built on a proprietary metagenomic sequencing assay that runs on an Illumina NextSeq sequencer. Each kit contains 36 tests and is able to detect SARS-CoV-2 at a sensitivity of 500 copies per milliliter. With the CE mark in hand, Vision Medicals plans to focus on the European market.

The startup, based in Guangzhou, China, has been developing a CRISPR-based diagnostic test for tuberculosis.  Last September, the firm raised $14 million in a Series A financing round.

Vision Medicals also recently published a preprint on a CRISPR-based SARS-CoV-2 diagnostic test, named CRISPR-nCoV, which is different from its CE-marked test.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.